Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 461 Melanoma 300 Squamous Cell Carcinoma of Head and Neck 234 Parkinson Disease 4, Autosomal Dominant Lewy Body 189 Neoplasms 185 Breast Neoplasms 162 Triple Negative Breast Neoplasms 161 Neoplasm Metastasis 156 Lung Neoplasms 146 Colorectal Neoplasms 142 Carcinoma, Renal Cell 132 Head and Neck Neoplasms 123 Stomach Neoplasms 104 Ovarian Neoplasms 100 Carcinoma, Transitional Cell 91 Urinary Bladder Neoplasms 81 Pancreatic Neoplasms 81 Carcinoma, Hepatocellular 74 Endometrial Neoplasms 72 Uterine Cervical Neoplasms 63 Esophageal Neoplasms 57 Recurrence 52 Prostatic Neoplasms 49 Sarcoma 43 Carcinoma 42 Glioblastoma 40 Carcinoma, Squamous Cell 39 Small Cell Lung Carcinoma 38 Hodgkin Disease 36 Cholangiocarcinoma 35

Interventions

Leucovorin 2 Irinotecan 2 Fluorouracil 2 Cetuximab 2 spartalizumab 1 pembrolizumab 1 camrelizumab 1 Radiosurgery 1 Oxaliplatin 1 Oncolytic Virotherapy 1 KD025 1 IFL protocol 1 HLX07 1 Folfox protocol 1 Drug Therapy 1 CCT239065 1 Bevacizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

CRC × pembrolizumab × Clear all

NCT07511972 2026-04-06

Study of NGM707 in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies

NGM Biopharmaceuticals, Inc

Phase 2 Withdrawn

CRC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡